Verastem CEO Dan Paterson sells $12,470 in company stock

On November 3, 2026, Dan Paterson, the CEO of Verastem Inc., sold 1,299 shares of the company's common stock. The shares were sold at a price of $9.6 each, amounting to a total sale of $12,470. The stock had been trading near $9.38 at the time of the sale. This transaction occurred to fulfill statutory withholding requirements associated with the vesting of restricted stock units (RSUs).

Following the sale, Mr. Paterson directly owns 651,413 shares of Verastem common stock. The stock's current price of $9.6, while near its recent trading range, presents an opportunity as analysts have identified it as undervalued, with price targets ranging from $12 to $24 according to InvestingPro analysis.

In related news, Verastem Oncology reported its financial results for the third quarter of 2026. The company disclosed an adjusted loss of $0.72 per share, which exceeded analysts' expectations of a loss of $0.47 per share. Revenue for the quarter was $24.01 million, lower than the forecasted $26.83 million. Despite the shortfall, Verastem's revenue increased by 114% compared to the same quarter last year, driven mainly by the sales of the AVMAPKI/FAKZYNJA CO-PACK.

However, the financial results have prompted attention to the company's performance metrics, and there have been no recent upgrades or downgrades from analysts following this announcement. This update is part of ongoing communication from Verastem Oncology as the company manages its financial situation.